Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
12.35
+0.19 (1.56%)
At close: Apr 13, 2026, 4:00 PM EDT
12.35
0.00 (0.00%)
After-hours: Apr 13, 2026, 4:10 PM EDT
Design Therapeutics Employees
Design Therapeutics had 54 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
54
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,292,444
Market Cap
761.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 54 | 0 | - | 54 | 0 |
| Sep 30, 2025 | 55 | 1 | 1.85% | 55 | 0 |
| Jun 30, 2025 | 57 | 0 | - | 57 | 0 |
| Mar 31, 2025 | 56 | -1 | -1.75% | 56 | 0 |
| Dec 31, 2024 | 54 | -4 | -6.90% | 54 | 0 |
| Sep 30, 2024 | 54 | -3 | -5.26% | 54 | 0 |
| Jun 30, 2024 | 57 | -11 | -16.18% | 57 | 0 |
| Mar 31, 2024 | 57 | -7 | -10.94% | 57 | 0 |
| Dec 31, 2023 | 58 | 0 | - | 58 | 0 |
| Sep 30, 2023 | 57 | 1 | 1.79% | 57 | 0 |
| Jun 30, 2023 | 68 | 16 | 30.77% | 68 | 0 |
| Mar 31, 2023 | 64 | 20 | 45.45% | 64 | 0 |
| Dec 31, 2022 | 58 | 20 | 52.63% | 58 | 0 |
| Sep 30, 2022 | 56 | 23 | 69.70% | 56 | 0 |
| Jun 30, 2022 | 52 | 27 | 108.00% | 51 | 1 |
| Mar 31, 2022 | 44 | 23 | 109.52% | 44 | 0 |
| Dec 31, 2021 | 38 | 23 | 153.33% | 37 | 1 |
| Sep 30, 2021 | 33 | 18 | 120.00% | 33 | 0 |
| Jun 30, 2021 | 25 | - | - | 25 | 0 |
| Mar 31, 2021 | 21 | - | - | 21 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Solid Biosciences | 121 |
| Lexicon Pharmaceuticals | 81 |
| Alto Neuroscience | 68 |
DSGN News
- 5 weeks ago - Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 7 weeks ago - Design Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 months ago - Design Therapeutics Appoints Justin Gover to Board of Directors - GlobeNewsWire
- 8 months ago - Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewsWire
- 8 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 11 months ago - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - GlobeNewsWire
- 11 months ago - Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - GlobeNewsWire